What is the appropriate management of rheumatic fever, including antibiotic therapy, anti‑inflammatory treatment, and secondary prophylaxis?

Rheumatic Fever Management

Initiate intramuscular benzathine penicillin G 1,200,000 units every 4 weeks as the gold standard for secondary prophylaxis, combined with anti-inflammatory therapy (aspirin with or without corticosteroids for 12 weeks) for acute episodes, and eradicate any residual streptococcal infection with a full therapeutic course of penicillin regardless of throat culture results. 1

Acute Phase Management

Initial Antibiotic Therapy

• Eradicate residual Group A Streptococcus with a full therapeutic course of penicillin even if throat cultures are negative at diagnosis 1
• This must be completed before starting long-term prophylaxis
• Treat any streptococcal infections in household contacts promptly 1

Anti-Inflammatory Treatment

• Aspirin with or without corticosteroids for total duration of 12 weeks to control the inflammatory process 2
• The goal is to relieve symptoms and potentially mitigate cardiac valve damage 3
• Important caveat: No treatment has been proven to alter disease course or prevent progression to chronic rheumatic heart disease 4

Chorea Management

• Treat according to severity when present
• Continue therapy for 2-3 weeks after clinical improvement 2

Secondary Prophylaxis: The Critical Component

First-Line Regimen

Intramuscular benzathine penicillin G is superior to all oral alternatives and should be the default choice 1, 5:

• Dose: 1,200,000 units every 4 weeks in the United States 1
• High-risk populations: Every 3 weeks in areas with particularly high rheumatic fever incidence 1
• Recurrent cases: Every 3 weeks if recurrence occurs despite adherence to 4-week regimen 1

The evidence is compelling: intramuscular penicillin reduces rheumatic fever recurrence approximately 10 times more effectively than oral antibiotics (0.1% vs 1% recurrence rate) 5. Even compared to no antibiotics, prophylaxis substantially reduces recurrence risk (0.7% vs 1.7%) 5.

Alternative Oral Regimens (Lower Risk Patients Only)

Penicillin V (first choice for oral therapy):

• 250 mg twice daily for children and adults 1
• Consider switching to oral prophylaxis only in late adolescence/young adulthood after ≥5 years attack-free 1
• Critical limitation: Higher recurrence risk than intramuscular route even with perfect adherence 1

For penicillin allergy:

• Sulfadiazine: 0.5 g once daily if ≤27 kg; 1 g once daily if >27 kg 1
• Contraindicated in late pregnancy due to bilirubin displacement 1
• Sulfisoxazole is acceptable equivalent 1

For penicillin AND sulfonamide allergy:

• Macrolides (erythromycin or clarithromycin) or azalides (azithromycin) 1
• Warning: Monitor QT interval; avoid concurrent cytochrome P-450 3A inhibitors (azole antifungals, HIV protease inhibitors, some SSRIs) 1

Duration of Prophylaxis: Risk-Stratified Approach

With Persistent Valvular Disease

10 years after last episode OR until age 40, whichever is longer 1:

• Consider lifelong prophylaxis for high-risk patients (crowded living, healthcare workers, parents of young children) 1
• Continue even after valve surgery including prosthetic replacement 1

With Carditis but NO Persistent Valvular Disease

10 years after last episode OR until age 21, whichever is longer 1

Without Carditis

5 years after last episode OR until age 21, whichever is longer 1

Special Consideration for Latent RHD

Intramuscular benzathine penicillin provides substantial benefit in early/mild RHD, reducing progression risk from 8.1% to 0.7% 5

Critical Management Pitfalls

Pain Management for Injections

• Benzathine penicillin injections are painful and cause some patients to discontinue 1
• Must be administered by competent clinicians using pain-minimization strategies 6
• Despite discomfort, life-threatening allergic reactions are rare and long-term benefits far outweigh risks 1

Adverse Event Profile

Compared to no antibiotics, prophylaxis:

• Probably increases hypersensitivity reactions and local injection reactions 5
• May not increase risk of anaphylaxis or sciatic nerve injury 5
• Does not affect mortality in late-stage RHD 5

Endocarditis Prophylaxis

Rheumatic heart disease alone does NOT require endocarditis prophylaxis per current AHA guidelines 1:

• Only indicated if prosthetic valves or prosthetic material used in valve repair
• For those requiring endocarditis prophylaxis while on penicillin prophylaxis: use non-penicillin agent (oral streptococci likely penicillin-resistant) 1
• Patients on benzathine penicillin should receive amoxicillin before high-risk dental/surgical procedures; use clindamycin if recent penicillin course or immediate hypersensitivity 3

Adherence is Everything

Most prophylaxis failures occur in non-adherent patients 1. Patients require repeated, careful instructions about the critical importance of continuing prophylaxis 1. The decision to discontinue must involve thorough discussion of risks/benefits and epidemiological factors 1.